Growth hormone therapy in children and adults

Pharmacological Reports

Volumn 59, Issue 5, 2007, Pages 500-516

  Krysiak, Robert ^a   Gdula Dymek, Anna ^a   Bednarska Czerwińska, Anna Bednarska ^a   Okopień, Bogusław ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Adults; Adverse effects; Children; Contraindications; Experimental administration; Growth hormone; Indications

Indexed keywords

ARGININE; CLONIDINE; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; GHRELIN; GLUCAGON; GLUCOSE; GLUTAMINE; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; HUMAN GROWTH HORMONE; INSULIN; LEVODOPA; NEUTROPIN DEPOT; PLACEBO; RECOMBINANT GROWTH HORMONE; SEROSIM; SOMATOMEDIN; SOMATREM; UNCLASSIFIED DRUG; ZORBITIVE;

ABDOMINAL OBESITY; ACHONDROPLASIA; ADENOHYPOPHYSIS; ADULT; ARTHRALGIA; BEDTIME DOSAGE; BODY FAT; BODY MASS; BONE DISEASE; BURN; CARPAL TUNNEL SYNDROME; CATCH UP GROWTH; CEREBRAL PALSY; CHILD; CHRONIC KIDNEY FAILURE; CLINICAL FEATURE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; CYSTIC FIBROSIS; DIABETES MELLITUS; DIET THERAPY; DOSAGE SCHEDULE COMPARISON; DRUG APPROVAL; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; FEVER; FOOD AND DRUG ADMINISTRATION; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; GROWTH HORMONE SECRETING CELL; GROWTH RATE; GYNECOMASTIA; HEADACHE; HORMONAL THERAPY; HORMONE RELEASE; HUMAN; HYPOCHONDROPLASIA; HYPOGLYCEMIA; HYPOPHOSPHATEMIA; INJECTION SITE CONTUSION; INJECTION SITE ERYTHEMA; INJECTION SITE NODULE; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; INTRACRANIAL HYPERTENSION; KIDNEY TRANSPLANTATION; LEAN BODY WEIGHT; LEG PAIN; LIPOATROPHY; MEDICAL DECISION MAKING; METABOLIC DISORDER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEVUS; NOONAN SYNDROME; PANCREATITIS; PARESTHESIA; PATIENT COMPLIANCE; PATIENT MONITORING; PERIPHERAL EDEMA; PRADER WILLI SYNDROME; PROVOCATION TEST; PULSATILE HORMONE RELEASE; RECOMMENDED DRUG DOSE; REM SLEEP; REVIEW; RISK BENEFIT ANALYSIS; SHORT BOWEL SYNDROME; SHORT STATURE; SIDE EFFECT; SINGLE DRUG DOSE; SKIN PIGMENTATION; SMALL FOR DATE INFANT; STRESS; TREATMENT DURATION; TREATMENT OUTCOME; TURNER SYNDROME; VOMITING; WASTING SYNDROME;

EID: 38049129744     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Abs R: Upgrade on the diagnosis of GH deficiency in adults. Eur J Endocrinol, 2003, 148, S3-S8.
2. Ali O, Shim M, Fowler E, Greenberg MS, Perkins D, Oppenheim W, Cohen P: Growth hormone therapy improves bone mineral density in children with cerebral palsy: A preliminary pilot study. J Clin Endocrinol Metab, 2007, 92, 932-937.
3. Argente J, Abusrewil SA, Bona G, Chiarelli F, Kelnar CJ, Skordis N, International Workshop on Management of Puberty for Optimum Auxological Results: Isolated growth hormone deficiency in children and adolescents. J Pediatr Endocrinol Metab. 2001, 14, 1003-1008.
4. Ari M, Bakalov VK, Hill S, Bondy CA: The effects of growth hormone treatment on bone mineral density and body composition in girls with Turner syndrome. J Clin Endocrinol Metab, 2006, 91, 4302-4305.
5. Bakalov VK, Van PL, Baron J, Reynolds JC, Bondy CA: Growth hormone therapy and bone mineral density in Turner syndrome. J Clin Endocrinol Metab, 2004, 89, 4886-4889.
6. Bidlingmaier M, Kim J, Savoy C, Kim MJ, Ebrecht N, de la Motte S, Strasburger CJ: Comparative pharmacokinetics and pharmacodynamics of a new sustained release growth hormone, LB03002, versus daily GH in adults with GH deficiency. J Clin Endocrinol Metab, 2006, 91, 2926-2930.
7. Bondy CA, The Turner Syndrome Consensus Study Group: Care of Girls and Women with Turner syndrome: A Guideline of the Turner Syndrome Study Group. J Clin Endocrinol Metab, 2007, 92, 10-25.
8. Bryant J, Loveman E, Cave C: Endocrinology trial design: adverse event reporting in randomised controlled trials of recombinant human GH in GH-deficient adults J Endocrinol, 2002, 175, 545-552.
9. Byrne TA, Wilmore DW, Iyer K: Growth hormone and an optimal diet with or without glutamine reduces parenteral nutrition in patients with short bowel syndrome. Ann Surg, 2005, 242, 655-661.
10. Chakraborty A: Noonan syndrome: a brief overview. Hosp Med, 2002. 63. 743-745.
11. Clayton PE, Cianfarani S, Czernichow P, Johanasson G, Rapaport R, Rogot A: Management of the child born small for gestational age through to adulthood: A consensus statement of the International Societv of Pediatric Endocrinology and the Growth Hormone Research Society. J Clin Endocritiol Metab, 2007, 92, 804-810.
12. Cohen P. Bright GM, Rogol AD, Kappelgaard A, Rosenfeld RG: Effects of dose and gender on the growth factor response to GH in GH-deficiency children: Implications for efficacy and safety. J Clin Endocrinol Metab, 2002. 81, 90-98.
13. Cummings DE, Merriam GR: Growth hormone therapy in adults. Amin Rev Med, 2003, 54, 513-533.
14. Dattani M, Preece M: Growth hormone deficiency and related disorders: insights into causation, diagnosis, and treatment, Lancet, 2004, 363, 1977-1987.
15. Davenport ML, Quigley CA, Bryant CG, Rubin K, Travers S, Geffner M, Thrailkill K: Effects of earlv growth hormone (GH) treatment in very young girls with Turner Syndrome (TS). Presented at 7th Join ESPE/LWPES Meeting; Lyon, France, 2005.
16. de Zegher F. Hokken-Koelega A: Growth hormone therapy for children born small for gestational age: Height gain is less dose-dependent over the long term than over the short term. Pediatrics, 2005, 115, 458-462.
17. de Zegher F, Ong K, Ibanez L: Growth hormone therapy in short children born small for gestational age. Horm Res, 2006, 65, 145-152.
18. Drake WM, Howell SJ, Monson JP: Optimizing GH therapy in adults and children. Endocr Rev, 2001, 22, 425-450.
19. Eiholzer U: Deaths in children with Prader-Willy syndrome. A contribution to the debate about the safety of growth hormone treatment in children with PWS. Horm Res, 2005, 63, 33-39.
20. Ferreira L, Souza S, Arnhold I: PTPN11 (Protein tyrosine phosphatase, nonreceptor type 11) mutations and response to growth hormone therapy in children with Noonan syndrome. J Clin Endocrinol Metab, 2005, 90, 5156-5160.
21. Festen DA, van Toorenenbergen A. Duivenvoorden HJ, Hokken-Koelega AC: Adiponectin level in prepubertal children with Prader-Willi syndrome before and after growth hormone therapy. J Clin Endocrinol Metab, 2007, Epub ahead of print.
22. Finkelstein BS, Imperiale TF, Speroff T, Marrero U, Radcliffe DJ, Cuttler L: EfIect of growdi hormone therapy on height in children with idiopathic short stature. A meta-analysis. Arch Pediatr Adolesc Med, 2002, 156, 230-240.
23. Finken MJJ, Dekker FW, de Zegber F, Wit JM: Long-term Height Gain of Prematurely Born Children with Neonatal Growth Restraint: Parallelism with the Growth Pattern of Short Children Born Small for Gestational Age. Pediatrics, 2006. 118, 640-643.
24. Giovannuci E, Pollak, M: Risk of the cancer after growth-hormone treatment. Lancet, 2002, 360. 268-269.
25. Goldstone AP: Prader-Willi syndrome: advances in genetics, pathophysiology and treatment. Trends Endocrinol Metab, 2004, 15, 12-20.
26. Gorman G. Fivush B. Frankenfield D, Frankenfield D, Wara: Short stature and growth hormone use in pediatric hemodialysis patients. Pediatr Nephrol, 2005, 20, 1794-1800.
27. Götherstörm G. Bengtsson B-A, Bosacus I, Johannsson J, Svensson J: A Ten-Year., Prospective Study of the Metabolic Effects of Growth Hormone Replacement in Adults. J Clin Endoerincif Metab, 2007, Feb 6, Epub ahead of print.
28. Haeusler G: Growth hormone therapy in patients with Turner syndrome. Horm Res, 1998. 49, Suppl 2, 62-66.
29. Haffner D, Schaefer F: Does recombinant growth hermone improve adult height in children with chronic renal failure? Semin Nephrol, 2001, 21, 490-497.
30. Haffner D, Wuhl E, Schaefer F: Factors predictive of the short- and long-term efficacy of growth hormone treatment in prepubertal children with chronic renal failure. The German Study Group for Growth Hormone Treatment in Chronic Renal Failure. J Am Soc Nephrol, 1998, 9, 1899-1907.
31. Haffner D, Schaefer F, Nissel R: Effect of growth hormone treatment on the adult height of children with chronic renal failure. German Study Group for Growth Hormone Treatment in Chronic Renal Failure. N Engl J Med, 2000, 343, 923-930.
32. Hardin DS, Ellis K, Dyson M, McConnel R, Rice J, Seilheimer DK: Growth hormone improves clinical status in children with cystic fibrosis - results of a randomized controlled trial. J Pediatr, 2001, 139, 636-642.
33. Hardin M Gil improves growth and clinical status in children with cystic fibrosis a review of published studies. Eur J Endocrinol, 2004, 151, S81-S85.
34. Harris M, Hofman PL, Cutfield WS: Growth hormone treatment in children: review of safety and efficacy. Paediatr Drugs, 2004, 6, 93-106.
35. Hokken-Koelega AC, De Ridder MA, Lemmen RJ: Children born small for gestational age: do they catch up? Pediatr Res, 1995, 38, 267-271.
36. Holm VA, Cassidy SB, Butler MG: Prader-Willi syndrome: consensus diagnostic criteria. Pediatrics, 1993, 91, 398-402.
37. Hoybye C, Rudling M., Jacobsson H: Somatotropin therapy in adults with Prader-Willi syndrome. Treat Endocrinol, 2004, 3, 153-160.
38. Hoybye C, Rudling M: Long-term GH treatment of GH-deficient adults: Comparison between one and two daily injections J Endocrinol Invest, 2006, 29, 950-956.
39. Jeffcoate W: Growth hormone therapy and its relationship to insulin resistance, glucose intolerance and diabetes mellitus: a review of recent evidence. Drug Saf, 2002, 25, 199-212.
40. Jeppessen PB, Szkudlarck J, Hoy CE: Effect of high-dose growth hormone and glutamine on body composition, urine creatinine excretion, fatty acid absorption, and essential fatty acids status in short bowel patients: a randomized, double blind, cross-over, placebo-controlled study. Scan J Gastroenterol. 2001, 36, 48-54.
41. Johannsson G, Ahlmen J: End-stage renal disease: endocrine aspects of treatment. Growth Horm IGF Res, 2003, 13, Suppl A, S94-S101.
42. Johannsson G, Jorgensen JO: Safety aspects of growth hormone replacement in adults. Growth Horm IGF Res, 2001, 11, 59-71.
43. Johnston LB, Savage MO: Should recombinant human growth hormone therapy be used in short small for gestational age children? Arch Dis Child.. 2004, 89, 740-744.
44. Jorgensen JO, Norrelund H, Conceicao F: Somatotropin and glucose homeostasis. Considerations for patients management. Treat Endocrinol, 2002, 1, 229-234.
45. Karlberg JP, Albertsson-Wikland K, Kwan EY, Lam BC, Low LC: The timing of early postnatal catch-up growth in normal, full-term infants born short for gestational age. Horm Res, 1997, 48, Suppl 1, 17-24.
46. Kato Y, Murakami Y, Sohmiya M. Nishiki M: Regulation of human growth hormone secretion and its disorders. Intern Med, 2002, 41, 7-13.
47. Kelnar CJ: Growth hormone therapy for syndromic disorders. Clin Endocrinol (Oxf), 2001, 59, 12-21.
48. Kelnar CJ: The role of somatotropin therapy in children with Noonan syndrome. Treat Endocrinol, 2003, 2, 165-172.
49. Kemp SF, Fielder PJ, Attie KM, Blethen SL, Reiter EO, Ford KM: Pharmacokinetic and pharmacodynamic characteristic of a long-acting gowth hormone (GH) preparation (Nutropin Depot) in GH-deficient children. J Clin EDdocrinol Metab, 2004, 89, 3234-3240.
50. Kemp SF, Kuntze J, Attie KM, Maneatis, T., Butler S, Franc J, Lippe B: Efficacy and safety of long-term growth hormone treatment of idiopathic short stature. J Clin Endocrinol Metab, 2005, 90, 5247-5253.
51. Kirk JM, Bettes PR, Butler GE. Donaldson MD, Dunger DB, Johnston DI, Kelnar CJ: Short stature in Noonan syndrome: response to growth hormone therapy Arch Dis Child 2001, 84, 440-443.
52. Koltowska-Haggstrom M, Mattson AF, Monson JP: Does long-term GH replacement therapy in hypopituitary adults with GH deficiency normalise quality of life? Eur J Endocrinol, 2006, 155, 109-119.
53. Lanes R: Long-term outcome of growth hormone therapy in children and adolescents. Treat Endocrinol, 2004, 3, 53-66.
54. Lanfranco F. Gianotti L. Giordano R: Ageing, growth hormone and physical performance. J Endocrinol Invest, 2003, 26, 861-872.
55. Laron Z: Laron syndrome (primary growth hormone resistance or insensitivity): the personal experience 1958-2003. J Clin Endocrinol Metab, 2004, 89, 1031-1044.
56. Lengyel A: Novel mechanisms of growth hormone regulation: growth hormone-releasing peptides and ghrelin. Braz J Med Biol Res, 2006, 39, 1003-1011.
57. Loche S, Casini MR, Ubertini GM, Cappa M: Growth hormone treatment in non-growth hormone deficient children. J Endociinol Invest, 2005, 28, 193-198.
58. Mehta A, Hindmarsh PC: The use of somatropin (recombinant growth hormone) in children of short stature. Paediatr Drugs, 2002, 4, 37-47.
59. Messing B, Blethen S, DiBase JK, Matarese LE, Steiger E: Treatment of adult short bowel syndrome with recombinant human growth hormone. A review of clinical studies. J Clin Gastroenterol, 2006, 40, S75-S84.
60. Miller J, Silverstein J. Shuster J: Short-term effects of growth hormone on sleep abnormalities in Prader-Willi syndrome. J Clin Endocrinol Metab, 2006, 91, 413-417.
61. Mills JL, Schonberger LB, Wysowski DK: Long-term mortality in the United States cohort of pituitary-derived growth hormone recipients. J Pediatr, 2004 144, 430-436.
62. Molitch ME: Pituitary diseases in pregnancy. Semin Perinatol. 1998, 22, 457-470.
63. Motlich ME: Diagnosis of GH deficiency in adults - how good do the criteria need to be? J Clin Endocrinol Metab. 2002, 87, 473-476.
64. Orrego JJ, Barkan AL: Pituitary disorders. Drug treatment options. Drugs, 2000, 59, 93-106.
65. Pandian R. Nakamoto JM: Rational use of the laboratory for childhood and adult growth hormone deficiency. Clin Lab Med, 2004, 24, 141-174.
66. Parekh NR, Steiger E: Criteria for the use of recombinant human growth hormone in short bowel syndrome. Nutr In Clinical Practice, 2005, 20, 503-508.
67. Przkora R. Herndon DN, Suman OE, Jeschke MG, Meyer WJ, Chinkes DL: Beneficial effects of extended growth hormone treatment after hospital discharge in pediatric burn patients. Ann Surg, 2006, 243, 796-803.
68. Root AW. Root MJ: Clinical pharmacology of human growth hormone and its secretagogues. Curr Drug Targets Immune Endocr Metabol Disord, 2002, 2, 27-52.
69. Saenger P, Wikland KA, Conway GS, Davenport M, Gravholt CH, Hintz R, Hovatta O: Recommendations for the diagnosis and management of Turner syndrome. J Clin Endiocrinol Metab, 2001, 86, 3061-3069.
70. Scolapio JS, Camilleri M. Fleming CR: Effect of growth hormone, glutamine, and diet on body composition in short bowel syndrome; a randomized controlled study. Gastroenterology, 1997, 113, 1074-1081.
71. Shalet SM, Toogood A, Rabim A: The diagnosis of growth hormone deficiency in children and adults. Endocr Rev, 1998, 19, 203-223.
72. Shimon I: Growth hormone replacement for adult growth hormone deficiency. Expert Opin Pharmacother, 2003, 4, 1977-1983.
73. Sizonenko PC, Clayton PE, Cohen P. Hintz RT, Tanaka T, Laron Z,: Diagnosis and management of growth hormone deficiency in childhood and adolescence. Part 1: Diagnosis of growth hormone deficiency. Growth Horm IGF Res, 2001, 11, 137-165.
74. Soriano-Guillen L, Coste J, Ecosse E: Adult height and pubertal growth in Turner syndrome after treatment with recombinant growth hormone. J Clin Endocrinol Metab, 2005, 90, 5197-5204.
75. Slavrou S, Kleinberg DL: Diagnosis and management of growth hormone deficiency in adults. Endocrinol Metab Clin North Am, 2001, 30, 545-563.
76. Steiger E, DiBaise JK, Messing B, Matarese LE, Blethen S: Indications and recommendations for the use of recombinant human growth hormone in adult short bowel syndrome patients on parenteral nutrition. J Clin Gastroenterol, 2006, 40, S99-S106.
77. Swerdlow AJ, Higgins CD: Adlard P: Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85, a cohort study. Lancet, 2002. 360, 273-277.
78. Sybert VP, McCauley E: Turner's Syndrome. N Eng J Med, 2004, 351, 1227-1238.
79. Takala J, Ruokonen E, Webster NR: Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med, 1999, 341, 785-792.
80. The Canadian Growth Hormone Advisory Committee: Impact of growth hormone supplementation on adult height in Turner syndrome: results of the Canadian randomized controlled trial. J Clin Endocrinol Metab, 2005, 90, 3360-3366.
81. van Gool SA, Kamp GA. Visser-van Balen H. Mul D., Waelkens J, Jansen M: Final height outcome following 3 years of growth hormone mid gonadotropine releasing hormone agonist treatment in short adolescents with relatively early puberty. J Clin Endocrinol Metab, 2007, Epub ahead of print.
82. Vance ML. Mauras N: Growth hormone therapy in adults and children. N Engl J Med, 1999, 341, 1206-1216.
83. Neidhuis JD, Anderson SM, Shah N: Neurophysiological regulation and target-tissue impact of the pulsatile mode of growth hormone secretion in the human. Growth Horm IGF Res, 2001, 11, Suppl A, S25-S37.
84. Verhelst J, Abs R: Long-term growth hormone replacement therapy in hypopituitary adults. Drugs, 2002, 62, 2399-2412.
85. Wit JM: Growth hormone therapy. Best Pract Res Clin Endocrinol Metab, 2002, 16, 483-503.
86. Wuhl E, Schaefer F: Effects of growth hormone in patients with chronic renal failure: experience in children and adults, Horm Res. 2002, 58, Suppl 3, 35-38.
87. Zucchini S, Pirazzoli P, Baronio F, Gennari M, Bal MO, Balsamo A: Effects on adult height of pubertal growth hormone retesting and withdrawal of therapy in patients with previously diagnosed growth hormone deficiency. J Clin Endocrinol Metab, 2006, 91, 4271-4276.